Source: Eur Respir J 2011; 37: 129-135
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
Scherpereel A., Berghmans T., Lafitte J.J., Colinet B., Richez M., Bonduelle Y., Meert A.P., Dhalluin X., Leclercq N., Paesmans M., Willems L., Sculier J.P.. Valproate–doxorubicin: promising therapy for progressing mesothelioma. A phase II study. Eur Respir J 2011; 37: 129-135

Member's Comments

No comment yet.

Related content which might interest you: Comparison of anticancer effects of a novel histone deacetylase (HDAC) inhibitor CG200745 and SAHA in non-small lung cancer cells Source: International Congress 2019 – Diagnostic procedures and biology of lung cancer Year: 2019 VAC chemotherapy with valproic acid for refractory/relapsing small cell lung cancer: a phase II study Source: ERJ Open Res 2015; 1: 00029-2015 Year: 2015 A 5-aza-2?-deoxycytidine/valproate combination induces cytotoxic T-cell response against mesothelioma Source: Eur Respir J 2011; 38: 1105-1116 Year: 2011 A phase II study with gemcitabine (GEM) plus irinotecan (CPT11) in malignant mesothelioma (MM): preliminary report Source: Eur Respir J 2002; 20: Suppl. 38, 186s Year: 2002 Clinical study for monochemotherapy of amrubicin, a topoisomerase II inhibitor, in patients with previously treated small cell lung cancer Source: Eur Respir J 2007; 30: Suppl. 51, 433s Year: 2007 A comparison between the toxic side effects of adriamycin, cyclophosphamide, and etoposide (ACE) and carboplatin with etoposide (CbE) in the treatment of small cell lung cancer (SCLC) Source: Eur Respir J 2003; 22: Suppl. 45, 65s Year: 2003 Histone deacetylase inhibitor panobinostat reduces hypoxia-related cisplatin resistance in NSCLC cells by HDAC-mediated Hifalpha destabilization Source: Annual Congress 2013 –Basic research on lung cancer Year: 2013 Suberoylanilide hydroxamic acid: a potential epigenetic therapeutic agent for lung fibrosis? Source: Eur Respir J 2009; 34: 145-155 Year: 2009 Late Breaking Abstract - Randomized phase III study of erlotinib compared to intercalated erlotinib with cisplatin and pemetrexed as first-line therapy for advanced EGFR mutated non-small cell lung cancer, the NVALT 17 study. Source: Virtual Congress 2021 – New clinical and biological developments in lung cancer Year: 2021 Pemetrexed (alimta) therapy in mesothelioma Source: Eur Respir J 2006; 28: Suppl. 50, 754s Year: 2006 Histone deacetylase inhibition significantly augments human mesothelioma cellular response to chemotherapeutic agents Source: Eur Respir J 2001; 18: Suppl. 33, 396s Year: 2001 A phase II trial in patients with extensive disease small-cell lung cancer with irinotecan, carboplatin and etoposide regimen as a first line treatment Source: Eur Respir J 2006; 28: Suppl. 50, 781s Year: 2006 Valproic acid improves second-line regimen of small cell lung carcinoma in preclinical models Source: ERJ Open Res 2015; 1: 00028-2015 Year: 2015 Topotecan in combination with carboplatin and etoposide as first line treatment in SCLC patients: a phase I/II study – final results Source: Annual Congress 2008 - Therapy of thoracic tumours Year: 2008 Phase I trial of pemetrexed, carboplatin and sorafenib as first-line treatment in patients with metastatic NSCLC Source: Annual Congress 2010 - Treatment of lung cancer Year: 2010 LATE-BREAKING ABSTRACT: A new treatment combining valproate acid (VA) plus doxorubicin (D) for patients with refractory or recurrent malignant mesothelioma (MM): a phase II study Source: Annual Congress 2009 - New insights in biology and treatment of pleural tumours Year: 2009 Multicentre phase II trial of paclitaxel, cisplatin, and etoposide with concurrent radiation for limited stage small cell lung cancer Source: Eur Respir J 2001; 18: Suppl. 33, 394s Year: 2001 Sequential monochemotherapy: vepesid (VP16) and carboplatin (CBDCA) in the treatment of elderly patients with small cell lung cancer (SCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 395s Year: 2001 Systemic treatment of malignant mesothelioma Source: Eur Respir Mon; 2009: 44: 419–434 Year: 2009 Phase II study of gemcitabine plus irinotecan as second-line chemotherapy in advanced non-small cell lung cancer Source: Annual Congress 2009 - Management of thoracic malignancies Year: 2009